anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the field of medicine, and especially relates to benzothiazine-thione derivatives, a preparation method thereof and a purpose thereof. The invention intends to solve a technical problem, that novel benzothiazine-thione derivatives are provided, wherein the derivatives have structures represented by a formula I. according to the invention, the benzothiazine-thione derivatives are novel compounds obtained on a basis of a large-scale selection. As an experiment result, the benzothiazine-thione derivatives represented by the formula I have substantial effects in inhibiting mycobacterium tuberculosis. The effects of the derivatives are similar to or even better than that of isoniazid (MIC90=0.8muM). The derivatives have mycobacterium tuberculosis resisting activities. With the derivatives and the preparation methods, choices are provided for the development and application of antitubercular agents.
The present invention relates to a compound plant estrogen preparation capable of delaying the aging of females and a preparation method thereof, particularly to a preparation capable of delaying the aging of females and a preparation method thereof. The preparation is prepared from kudzuvine root isoflavone, soybean isoflavone, biologic calcium carbonate, EDTA ferric sodium salt, palmleaf raspberry pruit and ginkgo leaf. In concrete technological processes, the prepared palmleaf raspberry pruit and the prepared ginkgo leaf are added with water, heated, decocted and filtrated, and a filtered solution is decocted and prepared into paste through stewing, filtration, deslagging, refrigeration and concentration. Then, the paste is dried and sterilized, and an extract is obtained. The extract, the kudzuvine root isoflavone, the soybean isoflavone, the biologic calcium carbonate, etc. are pulverized and pass through a sieve, and after the extract, the kudzuvine root isoflavone, the soybean isoflavone, the biologic calcium carbonate, etc. are mixed in a mixing machine, preparation granules are obtained. The drying, the sterilization and the split charging of the preparation granules are carried out at 80 DEG C, and the compound plant estrogen preparation of the present invention is obtained. The compound plant estrogen preparation of the present invention can replenish estrogen, and simultaneously, activate and restore female ovarian functions. The compound plant estrogen preparation of the present invention can promote estrogen secretion, has the function of antioxidation, can improve various symptoms caused by the aging of females, osteoporosis, anemia, etc., can remove free radicals and delay aging, and has the functions of blood fat reduction, blood pressure reduction, etc.
BACKGROUND: Polygenic prediction studies in continental Africans are scarce. Africa's genetic and environmental diversity pose a challenge that limits the generalizability of polygenic risk scores (PRS) for body mass index (BMI) within the continent. Studies to understand the factors that affect PRS variability within Africa are required.
METHODS: Using the first multi-ancestry genome-wide association study (GWAS) meta-analysis for BMI involving continental Africans, we derived a multi-ancestry PRS and compared its performance to a European ancestry-specific PRS in continental Africans (AWI-Gen study) and a European cohort (Estonian Biobank). We then evaluated the factors affecting the performance of the PRS in Africans which included fine-mapping resolution, allele frequencies, linkage disequilibrium patterns, and PRS-environment interactions.
RESULTS: Polygenic prediction of BMI in continental Africans is poor compared to that in European ancestry individuals. However, we show that the multi-ancestry PRS is more predictive than the European ancestry-specific PRS due to its improved fine-mapping resolution. We noted regional variation in polygenic prediction across Africa's East, South, and West regions, which was driven by a complex interplay of the PRS with environmental factors, such as physical activity, smoking, alcohol intake, and socioeconomic status.
CONCLUSIONS: Our findings highlight the role of gene-environment interactions in PRS prediction variability in Africa. PRS methods that correct for these interactions, coupled with the increased representation of Africans in GWAS, may improve PRS prediction in Africa.
Optimized pain relief allowing early mobilization is a prerequisite for enhanced recovery after surgery. Open colorectal surgery is associated with severe and prolonged postoperative pain, especially during mobilization. No analgesic technique has fulfilled all requirements of optimal efficacy: no side effects, low costs, high patient compliance, and improvement in outcome, and consequently, multimodal analgesic techniques have been introduced with a focus on opioid sparing to improve analgesia and recovery. Epidural analgesia (EA) has shown a marked benefit in controlling pain at mobilization, and significantly improves pain management when compared with systemic patient-controlled morphine analgesia. However, eligible patients may not benefit from it because of technical problems or failure of efficiency. Recently, continuous preperitoneal infusion of local anesthetic (CPA) has been shown to be an effective method to relief pain after open colorectal surgery, to reduced morphine consumption and accelerated postoperative recovery. However, this technique has never been evaluated in a fast-track program (ERAS protocol). Moreover, continuous preperitoneal infusions of local anesthetic and epidural analgesia have never been compared.

The purpose of this randomized and double-blinded study is to compare these two techniques on pain control during mobilization, as a prerequisite for enhanced recovery after open colorectal surgery: 1- CPA group: continuous preperitoneal administration of 0.2% ropivacaine using a multilobed catheter positioned between the previously closed parietal peritoneum and the underside of the transversalis fascia + intravenous morphine (patient-controlled analgesia, PCA) as a rescue; 2- EA group: epidural infusion of 0.2% ropivacaine (patient-controlled epidural analgesia, PCEA) + continuous preperitoneal administration of 0.9% saline.
INTRODUCTION: Pregnancy-associated gynecological cancer (PAGC) refers to cancers of the ovary, uterus, fallopian tube, cervix, vagina, and vulva diagnosed during pregnancy or within 12 months postpartum. We aimed to describe the incidence of, and perinatal outcomes associated with, invasive pregnancy-associated gynecological cancer.
MATERIAL AND METHODS: We conducted a population-based historical cohort study using linked data from New South Wales, Australia. We included all women who gave birth between 1994 and 2013, with a follow-up period extending to September 30, 2018. Three groups were analyzed: a gestational PAGC group (women diagnosed during pregnancy), a postpartum PAGC group (women diagnosed within 1 year of giving birth), and a control group (women with control diagnosis during pregnancy or within 1 year of giving birth). We used generalized estimation equations to compare perinatal outcomes between study groups.
RESULTS: There were 1 786 137 deliveries during the study period; 70 women were diagnosed with gestational PAGC and 191 with postpartum PAGC. The incidence of PAGC was 14.6/100 000 deliveries and did not change during the study period. Women with gestational PAGC (adjusted odds ratio [aAOR] 6.81, 95% confidence interval [CI] 2.97-15.62) and with postpartum PAGC (aOR 2.65, 95% CI 1.25-5.61) had significantly increased odds of a severe maternal morbidity outcome compared with the control group. Babies born to women with gestational PAGC were more likely to be born preterm (aOR 3.11, 95% CI 1.47-6.59) and were at increased odds of severe neonatal complications (aOR 3.47, 95% CI 1.45-8.31) compared with babies born to women without PAC.
CONCLUSIONS: The incidence of PAGC has not increased over time perhaps reflecting, in part, the effectiveness of cervical screening and early impacts of human papillomavirus vaccination programs in Australia. The higher rate of preterm birth among the gestational PAGC group is associated with adverse outcomes in babies born to these women.
The invention provides antibody arrays specific for target antigens. Methods for discovery and compositions comprising native human antibodies, arrays comprising such antibodies, immortalized B cells expressing such antibodies and non-immortalized B cell libraries comprising B cells expressing such antibodies are provided. The invention provides a method for screening monoclonal antibodies for functional effects on cell surface molecules such as receptors using antibody repertoire arrays specific for target cell surface molecules. Functional antibodies directed to a target and therapeutics derived from such antibodies are also provided. High throughput and parallel screening for potentially therapeutic antibodies are provided. Antibodies directed to functional epitope clusters corresponding to a target and vaccines and therapeutics derived from such antibodies are also provided.
The study is a single dose, randomized, three-way crossover study in 30 healthy subjects, with equal numbers of males and females (minimum of 13 of either gender). Drop-outs will not be replaced. The three doses of medication given in the study (a single dose in each of the three study periods) will each be separated by a washout period of at least 7 calendar days. In each study period, eighteen (18) blood samples for pharmacokinetic analysis will be taken over 12 hours. Blood samples will be centrifuged and concentrations of ibuprofen (R-enantiomer and S-enantiomer) in plasma will be measured using a validated chromatographic assay. Pharmacokinetic parameters will be calculated from plasma concentration data \[R-enantiomer, S-enantiomer and total (sum of both enantiomers)\]. The rate and extent of absorption of the formulations will be compared.
ISOVUE (lopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space.

Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g., tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst).

Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion.

Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings.
The invention relates to a long-acting percutaneous absorption patch of rivastigmine, belonging to the technical field of medicines. The transdermal absorption patch is suitable for an application period of at least three days, and comprises a back lining layer, a medicine-carrying pressure-sensitive adhesive layer and an anti-adhesion layer. The medicine-carrying pressure-sensitive adhesive layer comprises rivastigmine free alkali or organic acid ionic liquid thereof, pressure-sensitive adhesive and percutaneous absorption enhancer. The weight of the rivastigmine free alkali or the organic acid ionic liquid accounts for 5-45 wt% of the total weight of the drug-loaded pressure-sensitive adhesive layer, the weight of the pressure-sensitive adhesive accounts for 50-90 wt% of the total weight of the pressure-sensitive adhesive layer, and the dosage of the percutaneous absorption enhancer accounts for 1-20 wt% of the total weight of the pressure-sensitive adhesive layer. Wherein, in the rivastigmine organic acid ionic liquid, the free alkali of rivastigmine is different from that of rivastigmineThe organic acid is in a molar ratio of 0.5:1 to 2: 1. In the patch, the accumulative penetration of the rivastigmine in 72 hours can reach 2.8mg/cm 2 . The patch has the advantages of simple preparation technology, low cost, constant-speed drug release, safety, effectiveness, good stability and convenient use.
Peripheral arterial disease (PAD), like other more central macrovascular diseases, is common in diabetes. PAD can lead to critical limb ischemia, either alone or when combined with an injury like a foot ulcer. The diabetic foot ulceration requires adequate circulation to heal; if the circulation is impaired such that the tissue oxygen demand exceeds supply, critical limb ischemia ensues, placing the limb at risk.

Most often, patients with critical limb ischemia, undergo multiple debridements in the operating room as well as vascular procedures, prior to reaching a viable level of amputation. This increases the patients' co-morbidities from repetitive exposure to anesthesia. Each debridement may be removing viable tissue and decreasing the length of the eventual amputation. Additionally, intraoperatively, the viability of the skin edges is a subjective assessment based on the surgeon's experience. That judgement can be inaccurate in 10-20% of cases and lad to reoperation. With the use of the SPY imaging system, a better assessment of not only macrovascularity, but also microvascularity of the tissues is able to be evaluated objectively. This helps identify the tissues that are underperfused.

The investigators are unaware of any literature evaluating the use of SPY imaging in the lower extremities intraoperatively during amputations or debridements. There are many studies published for the use of this technology during ophthalmic procedures , cerebral aneurismal repair, cardiac surgery and breast reconstruction. In cardiac surgery, the use of ICG based imaging has proven to be helpful in assessing the quality of bypass grafts and eliminating the need for radiography or catheter insertion (Reuthebuch et al., 2004). In ophthalmic procedures, ICG angiography has been fundamental in identifying many microvascular pathologies (Slakter, Yannuzzi, Guyer, Sorenson, \& Orlock, 1995). Furthermore, neurosurgeons have found that the use of ICG angiography is far more superior than DS angiography in identifying small vessels . As it has already been proven to be a good adjunct intraoperatively to visualize microvasculature, the investigators would like to apply this to the lower extremities. Identifying underperfused tissues intraoperatively can help the surgeon objectively decide an appropriate level of amputation/debridement to effectively minimize the number of revisional surgeries. Also, there are no studies that comprehensively evaluate and compare the effectiveness of other modalities that also attempt to assess vascularity with the SPY imaging system. The information gained could be pivotal and help to gain more insight in patients with difficult to heal wounds, especially in the presence of PVD.
POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 2). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
PURPOSE:To obtain an immunosuppressive agent, i.e. a substance having an excellent immunosuppressive effect by extracting mycelia or fruit bodies of MAITAKE (a kind of mushrooms which belongs to Grifola). CONSTITUTION:Mycelia or fruit bodies of MAITAKE are treated with hot water to obtain a soluble fraction. Alcohol is added to the extract and the fraction in the alcohol solution is collected after standing for a given hours. The fraction is then dissolved in water to obtain a material having an immunosuppressive effect. The material is immunosuppressive, i.e. activities of suppresser T cells are activated and inhibition of cancer immunoactivity is expressed.
Calcium Gluconate Injection is a clear, colorless to slightly yellow solution supplied sterile and nonpyrogenic in 100 mL Fill PAB® containers packaged 24 per case, as follows:

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.] Do not freeze.

Protect from light until use.

Preservative Free. Discard any unused portion in the Pharmacy Bulk Package within 4 hours after initial closure puncture.

Each dose dispensed from the Pharmacy Bulk Package must be used immediately.

The diluted solution must be used immediately.

NOTE: Supersaturated solutions are prone to precipitation. The precipitate, if present, may be dissolved by warming to 60° to 80°C, with occasional agitation, until the solution becomes clear. Shake vigorously. Allow to cool to room temperature before dispensing. Use injection only if clear immediately prior to use.
New derivatives of (1H-indol-3-ilmetil) dimethylamine with blocking activity of voltage dependent ca2 channels, preferably no-l, and its application in the treatment of diseases of the nervous system. {image-01} The present invention relates to compounds of general formula (I), and their use in the manufacture of medicaments useful for the treatment of diseases of the central and peripheral nervous system, such as neurodegenerative diseases, stroke, epilepsy, migraine, pain neuropathic or, in general, any disease produced by the alteration of the biological functions on which said products act. One of the therapeutic strategies to treat these diseases is the reduction of the entrance of ca2 through voltage dependent ca2 channels (ccdv). Thus, the compounds claimed in this invention regulate the homeostasis of ca2 in excitable cells, which is altered in these conditions. Among all types of ccdv, the compounds of general formula (I) act preferentially by the so-called non-l, so they would lack peripheral side effects of hemodynamic type, where the ccdv type l are predominant. The present invention can be framed in the field of the pharmaceutical industry. (Machine-translation by Google Translate, not legally binding)
BACKGROUND: Recent studies on machine learning have shown the potential to provide new methods with which to assess pain through the measurement of signals associated with physiologic responses to pain detected by wearables. We conducted a prospective pilot study to evaluate the real-world feasibility of using an AI-enabled wearable system for pain assessment with elderly patients with dementia and impaired communication.
METHODS: Sensor data were collected from the wearables, as well as observational data-based conventional everyday interventions. We measured the adherence, completeness, and quality of the collected data. Thereafter, we evaluated the most appropriate classification model for assessing the detectability and predictability of pain.
RESULTS: A total of 18 patients completed the trial period, and 10 of them had complete sensor and observational datasets. We extracted 206 matched records containing a 180 min long data segment from the sensor's dataset. The final dataset comprised 153 subsets labelled as moderate pain and 53 labelled as severe pain. After noise reduction, we compared the recall and precision performances of 14 common classification algorithms. The light gradient-boosting machine (LGBM) classifier presented optimal values for both performances.
CONCLUSIONS: Our findings tended to show that electrodermal activity (EDA), skin temperature, and mobility data are the most appropriate for pain detection.
Patients who have PDPH are manged by SPGB, they are assessed by NRS before the block, at 30 mins, 2h, 4h, 6h, 12h, and 24hours after block. The patients are also examined by TCD before and after the block.
Placebo syringes will contain 0.67ml of sterile water for injection. This will be injected daily for 12 weeks.
Drug ReactionwithEosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, includingclobazamtablets. These events can be fatal or life-threatening, particularly if diagnosis and treatment do not occur as early as possible. DRESS typically,although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ systeminvolvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection.Eosinophilia isoften present. Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that earlymanifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms arepresent, the patient should be evaluated immediately. Clobazam tablets should be discontinued if an alternative etiology for the signs or symptomscannotbe established [see Contraindications ( 4)].
Probands at WCM only who do not meet eligibility criteria for randomization to the intervention and control arms will be offered enrollment in a third arm, in which they will receive the intervention in addition to the option for referral to patient advocacy/support groups including FORCE: Facing Hereditary Cancer EMPOWERED, Sharsheret, SHARE, LatinaSHARE, Oneinforty, Susan G. Komen, Any Mountain, and Genetic Support Foundation, for additional guidance. Probands enrolled in this third arm only will be asked to share the names and contact information for all first, second, and third-degree relatives with whom they have shared their genetic testing results. We estimate enrolling up to 200 subjects into this exploratory third arm (50 probands and 150 Relatives including first, second, and third-degree relatives).
PURPOSE:To obtain spherical granular matter stably eluting or discharging the effective component of a powder without deactivating the same and controlling the elution and discharge properties of the effective component. CONSTITUTION:Granular, pref., spherical polyglycerine fatty acid ester with an m.p. of 40-80 deg.C and a powder are suspended to form a fluidized bed and fluidized while heated to temp. in the vicinity of the m.p. of polyglycerine fatty acid ester to obtain granular matter. The powder contains at least a drug active component. Polyglycerine fatty acid ester shows no crystalline polygonal shape and does not deactivate the drug active component. By changing the HLB of polyglycerine fatty acid ester, the elution and discharge properties of the drug active component can be controlled.